Redian新闻
>
有谁有好的inspector, broker 推荐? 芝加哥地区
avatar
有谁有好的inspector, broker 推荐? 芝加哥地区# Living
d*s
1
Hello,
My name is David. I am a SAS certified Advanced programmer and have been
working as Sr. Clinical SAS Programmer for years mostly in giant
pharmaceutical companies such as Novartis, Allergan, Bristol-Myers Squibb,
etc. and other Clinical Research Organizations. Through my career, I have
been covered more than 100 clinical studies from Phase I to Phase IV.
I could provide hands on SAS programmings for folks who wants to be a prof.
clinical SAS programmer in pharmaceutical industry.
Please refer to http://sastrain.weebly.com/
and contact me through email or left a voice message on phone I listed on
the above website.
1st half day(4 hours) free trial.
avatar
o*p
2
RT,

先谢谢了!
avatar
d*s
3
看起来反响不是很热烈。 现在SAS 的工作机会还是很多。我希望有很多中国朋友能够
进入这行,否则越来越多的工作就被该死印度人抢走。
avatar
k*o
4
可以联系 KellyZ (IL)喔。

【在 o******p 的大作中提到】
: RT,
: 急
: 先谢谢了!

avatar
d*s
5
Hello,
My name is David. I am a SAS certified Advanced programmer and have been
working as Sr. Clinical SAS Programmer for years mostly in giant
pharmaceutical companies such as Novartis, Allergan, Bristol-Myers Squibb,
etc. and other Clinical Research Organizations. Through my career, I have
been covered more than 100 clinical studies from Phase I to Phase IV.
I could provide hands on SAS programmings for folks who wants to be a
prof. clinical SAS programmer in pharmaceutical industry.
Please refer to http://sastrain.weebly.com/
and contact me through email or left a voice message on phone I listed on
the above website.
请注意,对远距离的学员我们提供学习期间免费住宿。
avatar
b*2
6
我也推荐KellyZ.

【在 o******p 的大作中提到】
: RT,
: 急
: 先谢谢了!

avatar
d*s
7
看起来反响不是很热烈。 现在SAS 的工作机会还是很多。我希望有很多中国朋友能够
进入这行,否则越来越多的工作就被该死印度人抢走。
avatar
o*p
8
谢谢.
avatar
d*s
9
五月班现在开始招生,欢迎报名参加。有问题请致电或站内短信。
avatar
K*z
10
Kellyguo, Bed 谢谢支持。
avatar
K*z
11
哦留了言给你, 请查收。

【在 o******p 的大作中提到】
: 谢谢.
avatar
c*u
12
try usinspect.com.

【在 o******p 的大作中提到】
: RT,
: 急
: 先谢谢了!

相关阅读
logo
联系我们隐私协议©2024 redian.news
Redian新闻
Redian.news刊载任何文章,不代表同意其说法或描述,仅为提供更多信息,也不构成任何建议。文章信息的合法性及真实性由其作者负责,与Redian.news及其运营公司无关。欢迎投稿,如发现稿件侵权,或作者不愿在本网发表文章,请版权拥有者通知本网处理。